TB-500 vs Thymosin beta-4

How they differ

Each row below repeats what the two profiles cite. It is not a ranking or a recommendation.

Side by side

TopicTB-500Thymosin beta-4
What it is

A synthetic, N-acetylated peptide matching amino acids 17 to 23 (LKKTETQ) of thymosin beta-4. FDA’s substance registry notes that its identity record does not imply regulatory review or approval.1,5

Human thymosin beta-4, also recorded as TMSB4 and TB4X in FDA’s substance registry.2

FDA status

Not FDA-approved

Not an FDA-approved drug1

Not FDA-approved. FDA staff recommended in May 2026 against adding TB-500 to the 503A compounding list, and FDA has not issued a final rule. Under an October 30, 2026 HHS draft enforcement-discretion policy, TB-500 acetate is one of six listed peptides; HHS says it does not intend to take enforcement action against licensed pharmacies, federal facilities or physicians that compound it under the policy’s conditions.1,4,6

Is TB-500 FDA-approved?

Not FDA-approved

No FDA approval reported2,3

No FDA approval is reported in the sources reviewed here. FDA’s compounding safety-risk page lists a thymosin beta-4 fragment, TB-500, among withdrawn nominations, but not thymosin beta-4 itself.2,3

Is thymosin beta-4 FDA-approved?

HHS compounding policy, October 30, 2026

In the policy: one of the six peptides it lists.4

Not among the six peptides the policy lists.4

HHS’s October 30, 2026 draft enforcement-discretion policy lists six peptides in its Appendix A: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. Thymosin beta-4 is not among them; TB-500 is a fragment of it.4,6

FDA compounding safety-risk page

Listed.

FDA’s compounding safety-risk page, last updated April 22, 2026, lists TB-500 among substances whose nominations were withdrawn and says FDA has not identified any human exposure data for it.3

Not listed.

FDA’s compounding safety-risk page, current as of April 22, 2026, lists “thymosin beta-4, fragment (LKKTETQ), also known as TB-500” among withdrawn nominations with possible safety risks. It does not list full-length thymosin beta-4.3

Kinds of studies cited

Animal and lab studies only

  • Animal or laboratory research A laboratory study in which TB-500 did not speed the closing of scratch wounds in cultured cells, while one of its breakdown products had a small effect.1
  • Animal or laboratory research A study in aged mice in which a related fragment without TB-500’s acetyl group improved wound closure. FDA says those results cannot be directly carried over to TB-500.1
  • Animal or laboratory research Studies in horses and laboratory models showing that TB-500 reaches the bloodstream and is broken down into smaller fragments.1
  • Registered trial without results A Phase 1/2 trial of TB-500 in atherosclerotic cardiovascular disease and endothelial dysfunction, listed as recruiting in its March 23, 2026 registry record, with no results posted.7

Smaller controlled human trials

  • Controlled human trial A randomized, double-masked, placebo-controlled Phase 2 trial in 72 people with moderate to severe dry eye (2015).8
  • Controlled human trial A randomized, double-masked, placebo-controlled Phase 3 trial in 18 people with neurotrophic keratopathy and a persistent corneal defect (2022).9
Records collected

1 ClinicalTrials.gov record and 4 PubMed records collected

7 ClinicalTrials.gov records and 25 PubMed records collected

Area of study

Tissue repair and wound healing1

Eyes8,9

Latest dated events
  1. HHS publishes notice of a draft enforcement-discretion policy whose Appendix A lists TB-500 among six peptide substances used in compounding.4,6
  2. FDA’s Pharmacy Compounding Advisory Committee discusses TB-500.10
  3. FDA staff date their evaluation recommending that TB-500 not be added to the 503A bulks list.1
  1. FDA’s compounding safety-risk page, as last updated, lists the TB-500 fragment but not thymosin beta-4 itself.3
  2. A Phase 3 trial of thymosin beta-4 in 18 people with neurotrophic keratopathy is published.9
  3. A Phase 2 dry eye trial of thymosin beta-4 in 72 people is published.8

PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.

Citations

Sources

Coverage and sources →

Numbered markers in the text point here. Each link opens the original public record.

  1. 1
    FDA briefing document for TB-500 ↗

    U.S. Food and Drug Administration · Official source · Source checked November 14, 2026

  2. 2
    Thymosin beta-4 substance identity record ↗

    FDA Global Substance Registration System · Official source · Source checked November 15, 2026

  3. 3
    Certain bulk drug substances for use in compounding that may present significant safety risks ↗

    U.S. Food and Drug Administration · Official source · Source checked November 14, 2026

  4. 4
    HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendix A (list of peptides) and Appendix B (identities and justifications) ↗

    U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026

  5. 5
    TB-500 substance identity record ↗

    FDA Global Substance Registration System · Official source · Source checked July 29, 2026

  6. 6
    Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances · notice of availability · 91 FR 68526 · October 30, 2026 ↗

    Federal Register · U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026

  7. 7
    ClinicalTrials.gov record NCT07487363 · retained source version 2026-03-23:eb4b60623fcf6b4ae3df79179184b1b2b5a5502180a2163da52ebf8c09c10e1e ↗

    ClinicalTrials.gov · Official source · Source checked August 14, 2026

  8. 8
    Thymosin beta 4 ophthalmic solution for dry eye: a randomized, placebo-controlled, Phase II clinical trial conducted using the controlled adverse environment (CAE) model (2015) · PMID 26056426 ↗

    Clinical Ophthalmology · Official source · Source checked November 15, 2026

  9. 9
    RGN-259 (Thymosin ß4) Ophthalmic Solution Promotes Healing and Improves Comfort in Neurotrophic Keratopathy Patients in a Randomized, Placebo-Controlled, Double-Masked Phase III Clinical Trial (2022) · PMID 36613994 ↗

    International Journal of Molecular Sciences · Official source · Source checked November 15, 2026

  10. 10
    July 23-24, 2026 Pharmacy Compounding Advisory Committee meeting ↗

    U.S. Food and Drug Administration · Official source · Source checked November 14, 2026